Initial apixaban dosing in patients with atrial fibrillation

Apixaban is a non–vitamin K oral anticoagulant approved for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). Current labeling recommends dose reduction based on patient age, weight, and renal function.

[1]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[2]  K. Furie,et al.  Dabigatran versus Warfarin in Patients with Atrial Fibrillation , 2009 .

[3]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[4]  G. Mead,et al.  Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. , 2011, Age and ageing.

[5]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[6]  C. Frost,et al.  Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. , 2013, British journal of clinical pharmacology.

[7]  A. Shenker,et al.  Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. , 2013, British journal of clinical pharmacology.

[8]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[9]  A. Shenker,et al.  Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban , 2015, Clinical Pharmacokinetics.

[10]  Moshe Hoshen,et al.  Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Non‐Valvular Atrial Fibrillation , 2015, Journal of the American Heart Association.

[11]  J. Mega,et al.  Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments , 2015, The Lancet.

[12]  S. Goldhaber,et al.  Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. , 2016, The American journal of medicine.

[13]  D. Singer,et al.  Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes , 2016 .

[14]  A. Camm,et al.  XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation , 2015, European heart journal.

[15]  G. Lip,et al.  Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. , 2016, The New England journal of medicine.

[16]  A. Shenker,et al.  Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban , 2016, Journal of clinical pharmacology.

[17]  L. Fratiglioni,et al.  Atrial fibrillation and use of antithrombotic medications in older people: A population-based study. , 2017, International journal of cardiology.

[18]  T. Zima,et al.  Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions. , 2017, Current drug metabolism.

[19]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[20]  Gregory Y H Lip,et al.  Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. , 2017, Annals of translational medicine.

[21]  E. Grp.  2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European , 2019 .